Dr. Mason is Director of the Cancer Imaging Program at UT Southwestern with over 20 year's experience in cancer imaging, therapy, and tumor pathophysiology. He is Professor of Radiology and member of the Simmons Comprehensive Cancer Center. He serves on faculty of graduate programs in Biomedical Engineering, Molecular Biophysics and Cancer Biology. Dr. Mason and his research team have been supported for many years by NCI, DOD breast and prostate cancer initiatives, various foundations including The American Cancer Society, The Whitaker Foundation, and The Mary Kay Ash Foundation and most recently CPRIT. Dr. Mason’s primary research interest is prognostic radiology- developing and implementing methods for predicting optimal cancer therapy and assessing early response to treatment. Current investigations focus on development of oxygen sensitive MRI in pre-clinical breast, prostate and lung cancer as well as translation to human lung and prostate cancer. Dr. Mason is a recognized expert in the development of novel MR and optical reporter starategies with notable innovations in 19F NMR. Recent pre-clinical innovations include dynamic bioluminescent imaging related to vascular disputing agents and in vivo chemiluminescent imaging. Ongoing projects focus on novel vascular disrupting agents and assessment of pathophysiology of tumor response to therapy.
- Cambridge University - England (1983), Chemistry
- Graduate School
- Cambridge University - England (1986)
- Application of imaging methods to tumor development and response to therapy; development of NMR reporter molecules as probes of physiology and gene transfection; detoxification of xenobiotica; MR miscroscopy and tissue microstructure.
- Bioluminescent imaging
- gene therapy
- NMR- MRI
- Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
- Liu L, Mason RP, Gimi B Cancer Lett. 2014 Oct
- Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response.
- Hallac RR, Zhou H, Pidikiti R, Song K, Stojadinovic S, Zhao D, Solberg T, Peschke P, Mason RP Magn Reson Med 2013 Jun
- Simultaneous measurement of tissue oxygen level-dependent (TOLD) and blood oxygenation level-dependent (BOLD) effects in abdominal tissue oxygenation level studies.
- Ding Y, Mason RP, McColl RW, Yuan Q, Hallac RR, Sims RD, Weatherall PT J Magn Reson Imaging 2013 Jun
- New frontiers and developing applications in (19)F NMR.
- Yu JX, Hallac RR, Chiguru S, Mason RP Prog Nucl Magn Reson Spectrosc 2013 Apr 70 25-49
- Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T.
- Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT, Mason RP NMR Biomed 2012 Dec 25 12 1321-30
- Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors.
- Alhasan MK, Liu L, Lewis MA, Magnusson J, Mason RP PLoS ONE 2012 7 9 e46106
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
- Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG Integr Biol (Camb) 2011 Apr 3 4 375-87
- Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.
- Zhao D, Jiang L, Hahn EW, Mason RP Int. J. Radiat. Oncol. Biol. Phys. 2005 Jul 62 3 872-80
- Red-shifted emission from 1,2-dioxetane-based chemiluminescent reactions.
- Park JY, Gunpat J, Liu L, Edwards B, Christie A, Xie XJ, Kricka LJ, Mason RP Luminescence 2014 Sep 29 6 ii
- Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts.
- Liu L, Su X, Mason RP J Biomed Nanotechnol 2014 Aug 10 8 1545-51
19F NMR: clinical and molecular imaging applications. In Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications
V. D. Kodibagkar, R. Hallac, D. Zhao, J.-X. Yu, and R. P. Mason (2012). London, World Scientific Publishing Company
Non-Invasive Physiology and Pharmacology Using 19F Magnetic Resonance. In FLOURINE AND HEALTH
J.X. Yu, W. Cui, D. Zhao, and R. P. Mason (May 2008). Elsevier B.V.
Fluorocarbon Agents for Quantitative Multimodal Molecular Imaging and Targeted Therapeutics. In Molecular Imaging: Principles and Practice
S. A. Wickline, R. P. Mason, S. D. Caruthers, J. Chen, P. M. Winter, M. S. Hughes, G. M. Lanza (2010). People?s Medical Publishing House
MRI Hypoxia Measurements. In Functional Imaging in Oncology
S. Remmele, R. P. Mason, and J. P.B. O?Connor (2014). Heidelberg, Springer-Verlag
Innovative applications of reporter genes and gene reporters in prostate cancer. In Prostate Cancer Cells: Detection, Growth and Treatment
L. Liu, M. K. Alhasan, W. Cui, J. Magnusson, and R. P. Mason (2013). Hauppauge, NY, Nova Science Publishers
Honors & Awards
- Fellow of Royal Society of Chemistry
chartered scientist designation of the Science Council (2004)
- Lyndon Baines Johnson Award
American Heart Association (Texas Affiliate) (1993)
- Young Investigator Award at 5th International Society of Blood Substitutes Meeting
Presentation: Tumor oxygen tension: Measurement using OxygentTM as a 19F NMR probe at 4.7 T (1993)
Chartered Chemist of the Royal Society of Chemistry (1987)
- American Journal of Nuclear Medicine and Molecular Imaging (2011)
- Imaging in Medicine (2009)
- Letters in Drug Design & Discovery (2005)
- American Association for Cancer Research (1993)
- International Society of Magnetic Resonance in Medicine (1990)
- Royal Society of Chemistry (1987)